Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLA1 | P09884 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12729571 | 0.86 | ADORA3 (0.33) | — | |
| SCHEMBL12729600 | 0.82 | POLA1 (0.52) | KDM4EPOLA1TAS1R3TAS1R1 | |
| SCHEMBL12729593 | 0.80 | KDM4E (0.41) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL17833859 | 0.77 | POLB (0.47) | KDM4EPOLA1TAS1R3TAS1R1 | |
| SCHEMBL22984000 | 0.76 | KDM4E (0.40) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL25504661 | 0.76 | KDM4E (0.40) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL12531469 | 0.73 | POLB (0.34) | — | |
| SCHEMBL12729604 | 0.72 | STING1 (0.46) | STING1 | |
| SCHEMBL8620596 | 0.72 | STING1 (0.46) | STING1 | |
| SCHEMBL12729592 | 0.72 | HDAC1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168636-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-20160168636-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-9163053-B2 | Nucleotide analogs | FLUIDIGM CORPORATION (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163053-B2 | Nucleotide analogs | FLUIDIGM CORPORATION (US) | 2015-10-20 | — | — | US | disclosed |
| US-20110081647-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081647-A1 | NUCLEOTIDE ANALOGS | DUT, NT5C2, NUDT21 | KDM4E 1828/4885POLA1 100/4885TAS1R3 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.